Independent psychometric validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24)

Abstract

The endometrial cancer (EC)-specific Quality of Life module of the European Organization for Research and Treatment of Cancer (EORTC QLQ-EN24), was developed and validated in one study. We independently validated and assessed the psychometric properties of the instrument. Two hundred and eight women with EC before surgery, during adjuvant treatment and follow-up; in three different cancer centres completed the EORTC QLQ-C30 and the EN24. The questionnaire's completion rate was 100%, except sexuality items, that were answered by 35% of patients.All item-scale correlations for the multi-item scales exceeded the .4 criterion and correlated well with their own scale, while correlations with the other scales were low.The internal consistency of all multi-item scales were satisfactory (Cronbach's alpha coefficients ranging from .77 to .97). Discriminance for single-item scales was low. The QLQ-EN24 module discriminated well between clinically different patients, and there were no differences in quality of life questionnaire scales between patients with body mass index ≤30 when compared to those with >30. This validation study supports the reliability, as well as convergent and divergent validity of the EORTC QLQ-EN24. The module is a useful instrument for the assessment of QOL in patients with EC. However, data concerning sexuality should be interpreted with caution. K E Y W O R D Sendometrial cancer, quality of life, questionnaire, validation

The impact of adjuvant treatment with external beam radiotherapy and vaginal brachytherapy on health-related quality of life in patients with early-stage endometrioid endometrial carcinoma — initial results of a prospective study

“…The HRQL was also reported in many trials regarding adjuvant radiotherapy in endometrial carcinoma patients. The EORTC QLQ-C30 questionnaire to assess the HRQL was used in many well-known trials [10,17], but the EORTC QLQ-EN24 module for endometrial carcinoma patients is a relatively new tool with only a few trials reported recently [11,19]. In the PORTEC-1 trial, comparing the use of EBRT with no adjuvant treatment, EBRT was associated with long-term urinary and bowel symptoms and lower physical and role-physical functioning [9].…”

“…The HRQL can be measured using validated questionnaires. In patients with endometrial carcinoma, it can be done with the European Organization for Research and Treatment of Cancer (EORTC) core quality of life questionnaire (EORTC QLQ-C30) with Quality of Life Questionnaire-Endometrial Cancer module (EORTC QLQ-EN24) [11][12][13]. In the EORTC QLQ-C30 questionnaire, response scales ranging from 1 to 4 points for all items except for items 29 and 30 with response scales from 1 to 7 points.…”

Lifestyle and Empowerment Techniques in Survivorship of Gynaecologic Oncology (LETSGO study): a study protocol for a multicentre longitudinal interventional study using mobile health technology and biobanking

“… 47 A higher score reflects a better level of functioning and better QoL. Tumour-specific complaints are measured using the disease-specific supplements EORTC QLQ-EN24 49 for endometrial cancer, EORTC QLQ-OV28 50 for ovarian cancer, EORTC QLQ-CX24 51 for cervical cancer and EORTC VU-34 (under development, phase 4) for vulvar cancer. The EORTC instruments (except EORTC VU-34) have been used in studies of gynaecological cancer survivors, some of which were conducted in Norway.…”

Hubungan antara Faktor Klinikohistopatologi dan Kualitas Hidup Pasien Kanker Endometrium Pasca Operasi di RSUP Dr.Sardjito Yogyakarta Menggunakan Modul Kuesioner EORTC QLQ-C30 dan EN 24

“…Penilaian kualitas hidup pasien dilakukan dengan wawancara dan mengisi kuosioner berdasarkan modul EORTC QLQ-C 30 dan QLQ-EN 24. 23,24,25 Subjek penelitian adalah faktor-faktor klinikohistopatologi sebagai faktor prognosis dari kanker endometrium yang dapat mempengaruhi kualitas hidup penderitanya. Penelitian dilakukan di RSUP dr. Sardjito Yogyakarta selama enam bulan yang dimulai sejak ethical approval diterbitkan.…”